"I now have absolute proof that smoking even one marijuana cigarette is equal in brain damage to being on Bikini Island during an H-bomb blast."
Tell that to Obama, who inhaled frequently.
The journey on Cannabis education for me opened my eyes to many things, some of which I would like to say I was happily ignorant and beautifully blissful; this is not the case anymore.
So when I read NOW- Cannabis causes schizophrenia- I looked into it. This to me was the biggest joke to date. I wondered how they knew this and after reading time and time again - it appears it is NOT fact - far from it! It is a 'HUNCH' - a guess and a poor one at that. Well for any rational thinking human! Turns out that the ONLY way to PROVE - scientifically* that Cannabis causes Schizophrenia is to follow each person studied for over 20 years. ??? So I wondered- how the heck do they do that? THEY don't ! They follow up with them from time to time with a few questions - ARE you kidding me!? How can anyone make such a claim! It would be just as easy for me to claim about milk! REALLY!
They also note (in the fine print most times) that there are other factors.
SO the FACT is: NO they CANNOT prove Cannabis causes Schizophrenia- as a matter of FACT there is strong argument that young adolescence who DO have pre-existing schizophrenia often learn early that Cannabis actually helps them control their condition. Don't believe me - Research it! PLEASE! I did. Anyhow, I know there are many things, events, life lessons that have made me the person I am today - somewhat crazy - probably - but Cannabis was NOT one of them.
*One little note to leave you with - Alcohol on the other hand is increasingly being tied (scientifically) with the rise of dementia in people.
You sure don't see those headlines everyday!!
more on the subject: Study: Administration Of Non-Psychotropic Cannabinoid Mitigates Psychotic Symptoms In SchizophrenicsMannheim, Germany: The administration of the non-psychotropic plant constituent cannabidiol (CBD) is associated with a significant reduction in psychotic symptoms in patients with schizophrenia, according to clinical trial data published in the journal Translational Psychiatry.
An international team of researchers from Germany and the United States performed a four week, double-blind, randomized clinical trial assessing the clinical relevance of cannabidiol versus amisulpride, a potent antipsychotic agent, in patients with acute schizophrenia.
Researchers reported that the administration of either substance was associated with significant clinical improvement, but they acknowledged, "[C]annabidiol displayed a markedly superior side-effect profile."
Amisulpride is categorized as "one of the most effective drugs currently in use for the treatment of schizophrenia."
Investigators concluded, "Our results provide evidence that the non-cannabimimetic constituent of marijuana, cannabidiol, exerts clinically relevant antipsychotic effects that are associated with marked tolerability and safety, when compared with current medications. ... The results ... potentially represent a completely new mechanism in the treatment of schizophrenia."
A review of CBD's safety profile in humans, published online in 2011 in the scientific journal Current Drug Safety, concluded that the cannabinoid is non-toxic, safe, and well tolerated in humans, even in high doses.
Separate investigations of CBD have documented the cannabinoid to possess a variety of therapeutic properties, including anti-inflammatory, anti-diabetic, anti-epileptic, anti-cancer, and bone-stimulating properties.